HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
BIOBOARD - AUSTRALIA
Women: Hormone therapy won’t harm your head
Women do not suffer cognitive loss when taking hormone replacement therapy to treat symptoms of menopause, a new study finds.

Researchers tested the treatment for six months in early postmenopausal women between the ages of 49 and 55 who had never used HRT E2D—a combination of hormones estradiol and drospirenone. The examined HRT's effects on memory, language and concentration.

The treatment resulted in significant improvement in menopausal symptoms including hot flushes, night sweats, and sexual function, and it lowered blood pressure and weight in comparison to those who were treated with an identical placebo.

The women underwent cognitive assessment and were asked to perform mental tasks during a brain-imaging (MRI) scan. The researchers found no effect on the cognitive performance of early postmenopausal women.

Professor Susan Davis, director of the Women's Health Research Program in the Monash University School of Public Health and Preventive Medicine, says there had long been debate about the safety of hormone replacement therapies and the potential adverse effects on cognitive function in women.

Davis says memory and mood complaints were frequent in women after menopause due to oestrogen deficiency, including a lack of clarity of thought and memory or word-finding difficulties.

“These findings are reassuring for women,” Davis says.

“We report, for the first time, that drospirenone combined with estradiol has no overall effect on the cognitive performance of postmenopausal women examined over a 26-week period.

“Although hormone replacement therapy is no quick fix to the challenge of menopause, it does show that the E2D treatment can be useful in the overall management of menopause, and without adversely effecting cognitive ability.”

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Diabetics Technology
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy